Pregnyl 5000IU/amp 1 Ampulle by MSD

Usage

1. Calculate your total HCG requirement before opening any ampoule: a 14-day protocol at 500 IU every 48 hours requires 7 doses × 500 IU = 3,500 IU total; one 5,000 IU ampoule covers this with 1,500 IU reserve for adjustment.
2. Reconstitute the lyophilised powder by slowly injecting the supplied bacteriostatic diluent into the ampoule; swirl gently — never shake — to avoid denaturing the glycoprotein structure.
3. Draw the desired volume into an insulin syringe: at 1,000 IU/ml concentration (5 ml diluent), 500 IU corresponds to 0.5 ml — confirm on a calibrated syringe before injecting.
4. Administer subcutaneously into the abdomen or upper thigh, rotating injection sites across the 10–20 day HCG phase to prevent local tissue irritation.
5. Store the reconstituted ampoule capped in the refrigerator at 2–8 °C; label with the reconstitution date and discard any unused solution after 30 days.
6. Transition to your chosen SERM (tamoxifen or clomiphene) within 24–48 hours of the final HCG injection, completing the modern two-stage PCT sequence without a gap that would allow testosterone to decline again.

Warnings

Frequently asked questions

What does a modern two-stage PCT protocol involving HCG actually look like?

A modern two-stage PCT runs an HCG loading phase first — typically 500–1,000 IU subcutaneously every 48 hours for 10–20 days — followed immediately by a SERM phase using tamoxifen or clomiphene. This sequenced approach separates gonadotropin support from estrogen-receptor modulation, allowing each agent to act in its optimal hormonal environment rather than competing simultaneously.

How does modern PCT differ from the older SERM-only post-cycle approach?

Modern PCT protocols add a structured HCG phase before SERM administration, a distinction absent from older single-agent designs that started clomiphene or tamoxifen on day one off-cycle. The addition of a gonadotropin window rebuilds intratesticular testosterone concentrations progressively, providing a stronger hormonal baseline from which SERM therapy can then consolidate pituitary-gonadal axis function.

What role do SERMs play after the HCG phase in current evidence-based PCT?

SERMs like tamoxifen (20–40 mg/day) or clomiphene (25–50 mg/day) follow the HCG phase to suppress the negative feedback that excess estrogen exerts on the hypothalamus and pituitary. At this point, the testes are already producing testosterone again; SERMs ensure the pituitary continues releasing FSH and LH independently, locking in recovery without ongoing exogenous gonadotropin dependence.

Why does single-ampoule format matter for sterility when using HCG in PCT?

Each Pregnyl ampoule is a single-use, factory-sealed unit containing one lyophilised dose in a sterile, inert glass container. Opening a fresh ampoule for each injection session eliminates the contamination risk associated with multi-use vials, which accumulate particulate matter and microbial exposure over repeated punctures — a meaningful safety advantage when subcutaneous injections are performed over a 10–20 day PCT window.

How should reconstituted Pregnyl be stored to maintain potency throughout a PCT cycle?

Reconstituted Pregnyl solution must be refrigerated at 2–8 °C immediately after mixing and used within 30 days. The lyophilised powder in its sealed ampoule retains stability until the printed expiry date when stored at the same temperature range. Avoid freezing the reconstituted solution, as ice crystal formation degrades protein structure and reduces bioactive HCG concentration below the declared 5,000 IU label claim. (2) angle_used

Manufacturer

MSD (Merck Sharp & Dohme) is a globally licensed pharmaceutical manufacturer whose Pregnyl product line undergoes a multi-stage quality-control pipeline before distribution. Central to MSD's release criteria is HPLC-Verified chromatographic analysis: high-performance liquid chromatography confirms that the active HCG content falls within the pharmacopoeially specified potency range for the declared 5,000 IU label. Additionally, every sterile injectable batch is subjected to LAL (Limulus Amebocyte Lysate) endotoxin testing, ensuring pyrogen levels comply with EU GMP Annex 1 requirements for sterile medicinal products. The lyophilised ampoule format itself reflects MSD's stability engineering — freeze-drying the active protein extends shelf life and locks in bioactivity without preservatives that could interfere with reconstituted potency.